Back to Search Start Over

A MUC5B Gene Polymorphism, rs35705950-T, Confers Protective Effects Against COVID-19 Hospitalization but Not Severe Disease or Mortality.

Authors :
Verma A
Minnier J
Wan ES
Huffman JE
Gao L
Joseph J
Ho YL
Wu WC
Cho K
Gorman BR
Rajeevan N
Pyarajan S
Garcon H
Meigs JB
Sun YV
Reaven PD
McGeary JE
Suzuki A
Gelernter J
Lynch JA
Petersen JM
Zekavat SM
Natarajan P
Dalal S
Jhala DN
Arjomandi M
Gatsby E
Lynch KE
Bonomo RA
Freiberg M
Pathak GA
Zhou JJ
Donskey CJ
Madduri RK
Wells QS
Huang RDL
Polimanti R
Chang KM
Liao KP
Tsao PS
Wilson PWF
Hung AM
O'Donnell CJ
Gaziano JM
Hauger RL
Iyengar SK
Luoh SW
Source :
American journal of respiratory and critical care medicine [Am J Respir Crit Care Med] 2022 Nov 15; Vol. 206 (10), pp. 1220-1229.
Publication Year :
2022

Abstract

Rationale: A common MUC5B gene polymorphism, rs35705950-T, is associated with idiopathic pulmonary fibrosis (IPF), but its role in severe acute respiratory syndrome coronavirus 2 infection and disease severity is unclear. Objectives: To assess whether rs35705950-T confers differential risk for clinical outcomes associated with coronavirus disease (COVID-19) infection among participants in the Million Veteran Program (MVP). Methods: The MUC5B rs35705950-T allele was directly genotyped among MVP participants; clinical events and comorbidities were extracted from the electronic health records. Associations between the incidence or severity of COVID-19 and rs35705950-T were analyzed within each ancestry group in the MVP followed by transancestry meta-analysis. Replication and joint meta-analysis were conducted using summary statistics from the COVID-19 Host Genetics Initiative (HGI). Sensitivity analyses with adjustment for additional covariates (body mass index, Charlson comorbidity index, smoking, asbestosis, rheumatoid arthritis with interstitial lung disease, and IPF) and associations with post-COVID-19 pneumonia were performed in MVP subjects. Measurements and Main Results: The rs35705950-T allele was associated with fewer COVID-19 hospitalizations in transancestry meta-analyses within the MVP (N <subscript>cases</subscript>  = 4,325; N <subscript>controls</subscript>  = 507,640; OR = 0.89 [0.82-0.97]; P  = 6.86 × 10 <superscript>-3</superscript> ) and joint meta-analyses with the HGI (N <subscript>cases</subscript>  = 13,320; N <subscript>controls</subscript>  = 1,508,841; OR, 0.90 [0.86-0.95]; P  = 8.99 × 10 <superscript>-5</superscript> ). The rs35705950-T allele was not associated with reduced COVID-19 positivity in transancestry meta-analysis within the MVP (N <subscript>cases</subscript>  = 19,168/N <subscript>controls</subscript>  = 492,854; OR, 0.98 [0.95-1.01]; P  = 0.06) but was nominally significant ( P  < 0.05) in the joint meta-analysis with the HGI (N <subscript>cases</subscript>  = 44,820; N <subscript>controls</subscript>  = 1,775,827; OR, 0.97 [0.95-1.00]; P  = 0.03). Associations were not observed with severe outcomes or mortality. Among individuals of European ancestry in the MVP, rs35705950-T was associated with fewer post-COVID-19 pneumonia events (OR, 0.82 [0.72-0.93]; P  = 0.001). Conclusions: The MUC5B variant rs35705950-T may confer protection in COVID-19 hospitalizations.

Details

Language :
English
ISSN :
1535-4970
Volume :
206
Issue :
10
Database :
MEDLINE
Journal :
American journal of respiratory and critical care medicine
Publication Type :
Academic Journal
Accession number :
35771531
Full Text :
https://doi.org/10.1164/rccm.202109-2166OC